GSK5471713

PreclinicalSmall molecule

GSK

GSK5471713 is one of 2 small molecule programs targeting Neoplasms, Prostate. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoplasms, ProstateRecruiting

Neoplasms, ProstatePreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Neoplasms, Prostate

#DrugCompanyPhaseTrials

Risvutatug Rezetecan

NNader Sanai

Phase 3

1 2

GSK5471713

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

PreclinicalRecruiting

Neoplasms, Prostate

NCT07332455

Clinical

Trials by Indication[1]

Neoplasms, Prostate1 trial

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Recruiting· GSK logo

GSK·Preclinical·NCT07332455·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GSK5471713. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK5471713 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK5471713. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK

GSK5471713

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Neoplasms, Prostate1 trial

References

Drug Info

Quick Facts

Related News